BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shatilova A, Girshova L, Zaytsev D, Budaeva I, Mirolyubova Y, Ryzhkova D, Grozov R, Bogdanov K, Nikulina T, Motorin D, Zammoeva D, Efremova S, Ivanov V, Petukhov A, Alekseeva Y, Zaritskey A. The myeloid sarcoma treated by Venetoclax with hypomethylating agent followed by stem cell transplantation: rare case report. BMC Womens Health 2021;21:184. [PMID: 33933047 DOI: 10.1186/s12905-021-01328-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 De la Garza-Salazar F, Peña-Lozano SP, Gómez-Almaguer D, Colunga-Pedraza PR. Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor. J Oncol Pharm Pract 2023;29:493-7. [PMID: 35747932 DOI: 10.1177/10781552221110826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Maravalle D, Filosa A, Bigazzi C, Collina G, Galieni P. Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax. eJHaem 2022;3:517-520. [DOI: 10.1002/jha2.388] [Reference Citation Analysis]
3 Duminuco A, Maugeri C, Parisi M, Mauro E, Fiumara PF, Randazzo V, Salemi D, Agueli C, Palumbo GA, Santoro A, Di Raimondo F, Vetro C. Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field. Cancers (Basel) 2022;14:2186. [PMID: 35565314 DOI: 10.3390/cancers14092186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Arzoun H, Srinivasan M, Thangaraj SR, Thomas SS, Mohammed L. The Progression of Chronic Myeloid Leukemia to Myeloid Sarcoma: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.21077] [Reference Citation Analysis]
5 Antineoplastics. Reactions Weekly 2021;1866:46-46. [DOI: 10.1007/s40278-021-99742-6] [Reference Citation Analysis]